Smruthi Organics
Limited

Date: 04 March 2026

To
Corporate Relation Department
BSE Limited
P. J. Tower, Dalal Street,
Mumbai – 400 001.

Scrip Code: 540686

To
Listing Department
Metropolitan Stock Exchange of India Ltd
Building A, Unit 205A, 2nd Floor,
Piramal Agastya Corporate Park,
L.B.S Road, Kurla West, Mumbai – 400070

Symbol: SMRUTHI

Subject: Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Receipt of Attestation of Inspection from EDQM

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Smruthi Organics Limited has received an "Attestation of Inspection" from the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, following the inspection conducted at its flagship API manufacturing facility, Unit II, Solapur, Maharashtra from 27 August 2025 to 29 August 2025.
The attestation confirms compliance with the applicable European Good Manufacturing Practice (EU GMP) requirements under the CEP framework in respect of Amlodipine Besilate.

A detailed disclosure in this regard is enclosed herewith.
This is for your information and record.
Thanking you,

For Smruthi Organics Limited

Swapnil Eaga
Joint Managing Director

REGISTERED OFFICE : 'BALAJI BHAVAN' 165-A, RAILWAY LINES, SOLAPUR-413 001, MAHARASHTRA, INDIA
PHONE : 0091- 217-2310267, 2310367.
CORPORATE OFFICE : MUMBAI OFFICE : PH. : 022-24129211.
FACTORY : UNIT II : PLOT NO. A-27, M.I.D.C. CHINCHOLI, TAL. MOHOL, DIST. SOLAPUR - 413 255, MAHARASHTRA, INDIA.
PHONE : 0217-2357771, 2357772, ■ VISIT US : www.smruthiorganics.com
E-mail : eaga@smruthiorganics.com ■ CIN :- L24119PN1989PLC052562.

Smruthi Organics Limited

March 4, 2026

DISCLOSURE UNDER SEBI (LODR) REGULATIONS

Smruthi Organics Limited informs that it has received an "Attestation of Inspection" from the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, following the inspection conducted at its flagship API manufacturing facility, Unit II in Solapur, Maharashtra, from 27 August 2025 to 29 August 2025.

The attestation confirms that the facility operates in compliance with the application submitted to EDQM for Amlodipine Besilate and meets the applicable European Good Manufacturing Practice (EU GMP) requirements under the CEP and European regulatory framework.

This represents successful closure of the EDQM inspection process.

The Company believes this development significantly strengthens its position in regulated European and allied markets and enhances its credibility with global customers. The positive inspection outcome is expected to support business expansion, improve customer confidence, and create additional opportunities in regulated export markets.

The formal Certificate of Suitability (CEP) is currently under final administrative processing by EDQM. The Company will update the exchanges upon receipt of the CEP.

Smruthi Organics Limited remains committed to sustained regulatory excellence, quality leadership, and long-term value creation for its stakeholders.

For Smruthi Organics Limited

Swapnil Eaga
Joint Managing Director

REGISTERED OFFICE : 'BALAJI BHAVAN' 165-A, RAILWAY LINES, SOLAPUR-413 001, MAHARASHTRA, INDIA
PHONE : 0091- 217-2310267, 2310367.
CORPORATE OFFICE : MUMBAI OFFICE : PH. : 022-24129211.
FACTORY : UNIT II : PLOT NO. A-27, M.I.D.C. CHINCHOLI, TAL. MOHOL, DIST. SOLAPUR - 413 255, MAHARASHTRA, INDIA.
PHONE : 0217-2357771, 2357772, ■ VISIT US : www.smruthiorganics.com
E-mail : eaga@smruthiorganics.com ■ CIN :- L24119PN1989PLC052562.